Based on the Hisamitsu Pharmaceutical Co. Inc stock forecast from 0 analysts, the average analyst target price for Hisamitsu Pharmaceutical Co. Inc is not available over the next 12 months. Hisamitsu Pharmaceutical Co. Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Hisamitsu Pharmaceutical Co. Inc is Slightly Bullish , which is based on 7 positive signals and 4 negative signals. At the last closing, Hisamitsu Pharmaceutical Co. Inc’s stock price was USD 24.56. Hisamitsu Pharmaceutical Co. Inc’s stock price has changed by +0.00% over the past week, 0% over the past month and -14.67% over the last year.
No recent analyst target price found for Hisamitsu Pharmaceutical Co. Inc
No recent average analyst rating found for Hisamitsu Pharmaceutical Co. Inc
Company Overview Hisamitsu Pharmaceutical Co. Inc
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to approximately 40 countries and regions, including Asia, the United States of America, and the European area. Hisamitsu Pharmaceutical Co., Inc. was founded in 1847 and is headquartered in Tosu, Japan. Read Less
Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete's foot; and ALLEGRA FX, a sinus medication fo...Read More
Frequently Asked Questions About Hisamitsu Pharmaceutical Co. Inc (HTSUF) Stock
Stock Target Advisor's fundamental analysis for Hisamitsu Pharmaceutical Co. Inc's stock is Slightly Bullish .
HTSUF stock's dividend yield is 2.31%.
Our analysis grades HTSUF stock's dividend yield at F. This means that HTSUF stock's dividend yield is above 55% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this HTSUF may be a average dividend stock for its sector.
Unfortunately we do not have enough data on HTSUF's stock to indicate what its average analyst target is.
HTSUF stock's Price/Earning ratio is 20.64.
Our analysis grades HTSUF stock's Price / Earning ratio at F. This means that HTSUF stock's Price/Earning ratio is above 70% of the stocks in the Drug Manufacturers - Specialty & Generic sector in the OTC exchange.
Based on this HTSUF may be a overvalued for its sector.
The last closing price of HTSUF's stock was USD 24.56.
The most recent market capitalization for HTSUF is USD 1.86B.
Unfortunately we do not have enough analyst data on HTSUF's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Hisamitsu Pharmaceutical Co. Inc's stock.
As per our most recent records Hisamitsu Pharmaceutical Co. Inc has 0 Employees.
Hisamitsu Pharmaceutical Co. Inc's registered address is Tashirodaikan-machi 408, Tosu, Japan, 841-0017.
You can get more information about it from Hisamitsu Pharmaceutical Co. Inc's website at https://www.hisamitsu.co.jp.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for HTSUF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
